Terkko Navigator / -/ Feeds / " ( ( Eturauhasen kasvaimet )|( Prostatan kasvaimet )|( Eturauhastuumorit )|( Prostatan sy�"

JPM, Vol. 11, Pages 1061: Multiphoton Microscopy for Identifying Collagen Signatures Associated with Biochemical Recurrence in Prostate Cancer Patients

Cancers, Vol. 13, Pages 4690: Circulating Tumour Cell Numbers Correlate with Platelet Count and Circulating Lymphocyte Subsets in Men with Advanced Prostate Cancer: Data from the ExPeCT Clinical Trial (CTRIAL-IE 15-21)

Cancers, Vol. 13, Pages 5158: A Unified Transcriptional, Pharmacogenomic, and Gene Dependency Approach to Decipher the Biology, Diagnostic Markers, and Therapeutic Targets Associated with Prostate Cancer Metastasis

Prostate cancer: impact of the diagnosis on sexuality and the role of the HCP

The impact of the extent of the bone involvement on overall survival and toxicity in mCRPC patients receiving [¹⁷⁷Lu]Lu-PSMA-617: a WARMTH multicentre study

The importance of personalized medicine in urological cancers

Cancers, Vol. 13, Pages 3411: Maintaining Weight Loss in Obese Men with Prostate Cancer Following a Supervised Exercise and Nutrition Program—A Pilot Study.

The impact of visible tumor (PI-RADS ≥ 3) on upgrading and adverse pathology at radical prostatectomy in low risk prostate cancer patients: A biopsy core based analysis

The journey of radiotherapy dose escalation in high risk prostate cancer; conventional dose escalation to Stereotactic Body Radiotherapy (SBRT) boost treatments.

The effect of maximum tumor diameter by MRI on disease control in intermediate and high-risk prostate cancer patients treated with brachytherapy boost

The role of metformin, statins and diet in men on active surveillance for prostate cancer

Viruses, Vol. 13, Pages 2085: Towards a Precision Medicine Approach and In Situ Vaccination against Prostate Cancer by PSMA-Retargeted oHSV

Viruses, Vol. 13, Pages 2085: Towards a Precision Medicine Approach and In Situ Vaccination against Prostate Cancer by PSMA-Retargeted oHSV

Double-Negative Prostate Cancer Masquerading as a Squamous Cancer of Unknown Primary: A Clinicopathologic and Genomic Sequencing-Based Case Study.

A Proposal to Unify the Classification of Breast and Prostate Cancers Based on the Anatomic Site of Cancer Origin and on Long-term Patient Outcome.

A Proposal to Unify the Classification of Breast and Prostate Cancers Based on the Anatomic Site of Cancer Origin and on Long-term Patient Outcome

Cancers, Vol. 12, Pages 3254: The CHEK2 Variant C.349A>G Is Associated with Prostate Cancer Risk and Carriers Share a Common Ancestor

Cancers, Vol. 12, Pages 3254: The CHEK2 Variant C.349A>G Is Associated with Prostate Cancer Risk and Carriers Share a Common Ancestor

The evolutionary history of lethal metastatic prostate cancer.

BRCA2 Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian Cancers.

BRCA2 Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian Cancers.

BRCA2 Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian Cancers.

BRCA2 Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian Cancers.

BRCA2 Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian Cancers.

The effect of sample size on polygenic hazard models for prostate cancer.

The effect of sample size on polygenic hazard models for prostate cancer.

The rise of metastatic bone disease in Ireland

The CHEK2 Variant C.349A>G Is Associated with Prostate Cancer Risk and Carriers Share a Common Ancestor.

The <em>CHEK2</em> Variant C.349A&gt;G Is Associated with Prostate Cancer Risk and Carriers Share a Common Ancestor

The effect of sample size on polygenic hazard models for prostate cancer

The Global Burden of Cancer 2013.

Cancer incidence in persons with type 1 diabetes: a five-country study of 9,000 cancers in type 1 diabetic individuals.

Cancer incidence in persons with type 1 diabetes: a five-country study of 9,000 cancers in type 1 diabetic individuals.

Cancers, Vol. 12, Pages 2882: Genomic Instability Signature of Palindromic Non-Coding Somatic Mutations in Bladder Cancer

Cancers, Vol. 12, Pages 2882: Genomic Instability Signature of Palindromic Non-Coding Somatic Mutations in Bladder Cancer

Pre-clinical Research on Bladder Toxicity After Radiotherapy for Pelvic Cancers: State-of-the Art and Challenges

Cancers, Vol. 13, Pages 357: Estimation of the Potentially Avoidable Excess Deaths Associated with Socioeconomic Inequalities in Cancer Survival in Germany

Cancers, Vol. 13, Pages 448: Diagnosis and Treatment of Primary and Secondary Lung Cancers

The Adipose Tissue at the Crosstalk Between EDCs and Cancer Development

Cancers, Vol. 13, Pages 3967: PSMA-Targeting Radiopharmaceuticals for Prostate Cancer Therapy: Recent Developments and Future Perspectives

The Correlation between PSCA Expression and Neuroendocrine Differentiation in Prostate Cancer

The Correlation between PSCA Expression and Neuroendocrine Differentiation in Prostate Cancer

Cancers, Vol. 12, Pages 2854: Prostate Cancer Metastases Are Strongly Inhibited by Agonistic Epha2 Ligands in an Orthotopic Mouse Model

Cancers, Vol. 12, Pages 2854: Prostate Cancer Metastases Are Strongly Inhibited by Agonistic Epha2 Ligands in an Orthotopic Mouse Model

Cancers, Vol. 12, Pages 2984: Inflammation as a Driver of Prostate Cancer Metastasis and Therapeutic Resistance

Prostate-Specific Membrane Antigen-Targeted Radiopharmaceuticals in Diagnosis and Therapy of Prostate Cancer: Current Status and Future Perspectives

Comparison of biopsy under‐sampling and annual progression using hidden markov models to learn from prostate cancer active surveillance studies

Prostate cancer evolution from multilineage primary to single lineage metastases with implications for liquid biopsy